BRPI0415754A - processo para preparar aripiprazol de tamanho de partìcula médio desejado - Google Patents

processo para preparar aripiprazol de tamanho de partìcula médio desejado

Info

Publication number
BRPI0415754A
BRPI0415754A BRPI0415754-0A BRPI0415754A BRPI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A
Authority
BR
Brazil
Prior art keywords
aripiprazole
particle size
average particle
preparing
desired average
Prior art date
Application number
BRPI0415754-0A
Other languages
English (en)
Inventor
Margaret M Gleeson
Soojin Kim
Donald Kientzler
San Kiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0415754A publication Critical patent/BRPI0415754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0081—Use of vibrations, e.g. ultrasound
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA PREPARAR ARIPIPRAZOL DE TAMANHO DE PARTìCULA MéDIO DESEJADO". A presente invenção refere-se a um processo é fornecido para preparar aripiprazol estéril tendo um tamanho de partícula médio menor do que 100 mícrons porém preferivelmente maior do que 25 mícrons empregando um procedimento de cristalização a jato por colisão. O aripiprazol de massa resultante de tamanho de partícula desejado pode ser empregado para formar uma formulação de aripiprazol secada por congelamento estéril, que na constituição com água e injeção intramuscular libera aripiprazol durante um período de pelo menos cerca de uma semana e até cerca de oito semanas.
BRPI0415754-0A 2003-10-23 2004-10-20 processo para preparar aripiprazol de tamanho de partìcula médio desejado BRPI0415754A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51388603P 2003-10-23 2003-10-23
PCT/US2004/034634 WO2005041970A1 (en) 2003-10-23 2004-10-20 Process for making sterile aripiprazole of desired mean particle size

Publications (1)

Publication Number Publication Date
BRPI0415754A true BRPI0415754A (pt) 2006-12-19

Family

ID=34549310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415754-0A BRPI0415754A (pt) 2003-10-23 2004-10-20 processo para preparar aripiprazol de tamanho de partìcula médio desejado

Country Status (16)

Country Link
US (3) US20050152981A1 (pt)
EP (1) EP1675593B1 (pt)
JP (1) JP4875984B2 (pt)
KR (1) KR101121345B1 (pt)
CN (1) CN1871007A (pt)
AR (1) AR046142A1 (pt)
AU (1) AU2004284904B2 (pt)
BR (1) BRPI0415754A (pt)
CA (1) CA2543248C (pt)
CO (1) CO5670354A2 (pt)
ES (1) ES2632499T3 (pt)
IL (1) IL175008A (pt)
MX (1) MXPA06004333A (pt)
PE (1) PE20050810A1 (pt)
TW (1) TWI371274B (pt)
WO (1) WO2005041970A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
EP1613598B1 (en) * 2003-12-16 2011-10-19 Teva Pharmaceutical Industries, Ltd. Methods of preparing aripiprazole crystalline forms
DE202005020539U1 (de) * 2004-02-05 2006-09-28 Teva Pharmaceutical Industries Ltd. Aripiprazol
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1812397A1 (en) * 2004-11-18 2007-08-01 Synthon B.V. Process of making crystalline aripiprazole
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP2008537540A (ja) * 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
SG172690A1 (en) * 2006-04-28 2011-07-28 Schering Corp Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
ES2401603T3 (es) * 2006-10-24 2013-04-23 Cambrex Charles City, Inc. Procedimiento para preparar aripiprazol anhidro de tipo l
CN101172966B (zh) * 2007-04-06 2012-08-29 重庆医药工业研究院有限责任公司 一种阿立哌唑微晶的制备方法
PL2170279T3 (pl) 2007-07-31 2018-05-30 Otsuka Pharmaceutical Co., Ltd. Sposoby wytwarzania zawiesiny arypiprazolu i liofilizowanej formulacji
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
DE102009008478A1 (de) * 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
CN101507908B (zh) * 2009-04-09 2010-12-01 北京化工大学 微通道套管式装置及其应用
PT2550092T (pt) * 2010-03-22 2018-11-13 Instillo Gmbh Método para produção de micro ou nanopartículas
CN101816913B (zh) * 2010-05-20 2015-10-21 吴传斌 一种微球制造方法及制造设备
MX344235B (es) 2010-08-24 2016-12-07 Otsuka Pharmaceutical Co Ltd * Suspension y composicion en torta que contiene un derivado de carbostirilo y aceite de silicona y/o un derivado de aceite de silicona.
CN107625728A (zh) 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
CN103327968B (zh) * 2011-01-24 2016-09-07 大塚制药株式会社 含有以阿立哌唑作为有效成分的块状组合物的医疗用器具、及以阿立哌唑作为有效成分的块状组合物
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102850268B (zh) 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
WO2013000391A1 (zh) 2011-06-27 2013-01-03 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US9732068B1 (en) * 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
CA2959329C (en) * 2014-08-25 2023-06-27 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
CN107683131B (zh) * 2015-06-04 2021-09-28 克里蒂泰克公司 紫杉烷颗粒及其用途
EP3490529A1 (en) 2016-07-28 2019-06-05 Mylan Laboratories Ltd. Process for preparing sterile aripiprazole formulation
CN111346397B (zh) * 2020-03-11 2022-03-29 天津大学 适用于溶析结晶或反应结晶的加料设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
ES2251965T3 (es) * 1999-01-29 2006-05-16 Bristol-Myers Squibb Company Aparato y procedimiento de cristalizacion por ultrasonidos con chorros en colision.
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
CN1649655A (zh) * 2002-04-29 2005-08-03 布里斯托尔-迈尔斯斯奎布公司 雾化结晶系统
CN1652852A (zh) * 2002-05-10 2005-08-10 布里斯托尔-迈尔斯斯奎布公司 使用均化作用的结晶系统
AU2003230192A1 (en) * 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole

Also Published As

Publication number Publication date
CO5670354A2 (es) 2006-08-31
EP1675593B1 (en) 2017-05-31
US20130161848A1 (en) 2013-06-27
US9066848B2 (en) 2015-06-30
JP4875984B2 (ja) 2012-02-15
AU2004284904A1 (en) 2005-05-12
TWI371274B (en) 2012-09-01
TW200518783A (en) 2005-06-16
EP1675593A4 (en) 2007-04-25
AR046142A1 (es) 2005-11-23
IL175008A0 (en) 2006-08-20
MXPA06004333A (es) 2006-06-05
EP1675593A1 (en) 2006-07-05
CA2543248C (en) 2013-04-02
CA2543248A1 (en) 2005-05-12
US20110166352A1 (en) 2011-07-07
PE20050810A1 (es) 2005-09-25
KR20070090070A (ko) 2007-09-05
AU2004284904B2 (en) 2010-05-20
ES2632499T3 (es) 2017-09-13
US20050152981A1 (en) 2005-07-14
JP2007509153A (ja) 2007-04-12
CN1871007A (zh) 2006-11-29
WO2005041970A1 (en) 2005-05-12
IL175008A (en) 2014-11-30
KR101121345B1 (ko) 2012-03-09

Similar Documents

Publication Publication Date Title
BRPI0415754A (pt) processo para preparar aripiprazol de tamanho de partìcula médio desejado
BR0113520A (pt) Processo de preparação de ácidos n-aril-antranìlicos e seus derivados
BRPI0415531B8 (pt) formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
BR0001919A (pt) Composição de creme de limpeza de pele de modo que forme espuma, e, sistema de limpeza espumante de pele.
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
GT199900203A (es) Composiciones de celecoxib.
BRPI0901506A2 (pt) material de apoio para um instrumento cirúrgico
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
BRPI0400721A (pt) Composições que contêm sucralose
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BR0114186A (pt) Emprego de copolicarbonatos
BRPI0412489A (pt) composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
BRPI0415872A (pt) ácidos nucleìcos ligando especificamente à grelina bioativa
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
BR9915646A (pt) Intermediários, processo para a preparação de agente antibiótico macrolìdeo a partir deles
CY1109539T1 (el) Χρηση 5'-μεθυλοθειοαδενοσινης (μτα) στην προληψη και/η θεραπεια αυτοανοσων νοσων και/η απορριψης μοσχευματων
BR0315513A (pt) Composição farmacêutica injetável, processo para preparação de composição farmacêutica, e, uso de cefquinoma em um veìculo com liberação prolongada
BR0014577A (pt) Método e sistema para refrigerar e efetuar mudança no estado de uma mistura lìquida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/496; C07D 401/00; A61P 25/00

Ipc: A61K 31/496 (2011.01), C07D 401/00 (2011.01), A61P

B25A Requested transfer of rights approved

Owner name: OTSUKA PHARMACEUTICAL CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.